Konstantinos Xynos sold $64k of REPL
Chief Medical Officer at Replimune Group, Inc.. 7,952 shares at an average of $8.06, traded May 20, 2025, filed May 22, 2025.
Score components
- +15RoleOfficer
- +8Trade size$64k at market
- 0Share of holdings soldSold 5.1% of holdings
- +15Cluster6 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-25-052145, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 20, 2025 | SOpen-market sale Common Stock | -7,952 | $8.06 | $64k | 146,933 | May 22, 2025 |
Related signals
Other insiders at Replimune Group, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 29Weak | REPLsell Replimune Group, Inc. | Emily Luisa Hill Chief Financial Officer | $49k 9,154 shares | -6% | |
| 43Moderate | Replimune Group, Inc. | Philip Astley-Sparke director | $260k 32,279 shares | -2% | |
| 37Weak | Replimune Group, Inc. | Emily Luisa Hill Chief Financial Officer | $20k 2,535 shares | -2% | |
| 52Moderate | Replimune Group, Inc. | Sushil Patel Chief Executive Officer | $202k 25,105 shares | -7% | |
| 35Weak | Replimune Group, Inc. | Christopher Sarchi Chief Commercial Officer | $30k 3,749 shares | -3% | |
| 35Weak | Replimune Group, Inc. | Andrew Schwendenman Chief Accounting Officer | $26k 3,287 shares | -5% | |
| 15Weak | Replimune Group, Inc. | Sushil Patel Chief Executive Officer | $124k 10,000 shares | -5% | |
| 30Weak | Replimune Group, Inc. | Christopher Sarchi Chief Commercial Officer | $56k 5,207 shares | -6% | |
| 32Weak | Replimune Group, Inc. | Konstantinos Xynos Chief Medical Officer | $78k 7,246 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.